Patents by Inventor Clotilde Carlow
Clotilde Carlow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230407419Abstract: Compositions and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The compositions and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The compositions and methods are directed to labelled probes and their uses in Loop-Mediated Isothermal Amplification (LAMP) diagnostic tests to detect target DNA from the environment or from an individual and also to detect specific variants of the target DNA, both with similar sensitivity.Type: ApplicationFiled: August 18, 2023Publication date: December 21, 2023Applicant: New England Biolabs, Inc.Inventors: Nathan Tanner, Yinhua Zhang, Eric Hunt, Gregory Patton, Guoping Ren, Zhiru Li, Andrew Barry, Nicole Nichols, Catherine B. Poole, Harriet M. Strimpel, Ivan R. Correa, Jr., Clotilde Carlow, Esta Slayton, Thomas C. Evans, Jr.
-
Patent number: 11732315Abstract: Compositions and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The compositions and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The compositions and methods are directed to labelled probes and their uses in Loop-Mediated Isothermal Amplification (LAMP) diagnostic tests to detect target DNA from the environment or from an individual and also to detect specific variants of the target DNA, both with similar sensitivity.Type: GrantFiled: September 28, 2022Date of Patent: August 22, 2023Assignee: New England Biolabs, Inc.Inventors: Nathan Tanner, Yinhua Zhang, Eric Hunt, Gregory Patton, Guoping Ren, Zhiru Li, Andrew Barry, Nicole Nichols, Catherine B. Poole, Harriet M. Strimpel, Ivan R. Correa, Jr., Clotilde Carlow, Esta Slayton, Thomas C. Evans, Jr.
-
Publication number: 20230048863Abstract: Compositions and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The compositions and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The compositions and methods are directed to labelled probes and their uses in Loop-Mediated Isothermal Amplification (LAMP) diagnostic tests to detect target DNA from the environment or from an individual and also to detect specific variants of the target DNA, both with similar sensitivity.Type: ApplicationFiled: September 28, 2022Publication date: February 16, 2023Applicant: New England Biolabs, Inc.Inventors: Nathan Tanner, Yinhua Zhang, Eric Hunt, Gregory Patton, Guoping Ren, Zhiru Li, Andrew Barry, Nicole Nichols, Catherine B. Poole, Harriet M. Strimpel, Ivan R. Correa, JR., Clotilde Carlow, Esta Slayton, Thomas C. Evans, JR.
-
Patent number: 11525166Abstract: Kits and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The kits and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The kits and methods utilize in various combinations, reversible inhibitors of kit components, thermolabile enzymes, poloxamers, various salts, indicators and one or more Loop-Mediated Isothermal Amplification (LAMP) primer sets for detecting single and/or multiple targets and variants of the targets including SARS-CoV-2 targets and variants thereof in a single reaction. The kits and methods permit detection of the target nucleic with similar sensitivity regardless of the presence of undefined mutations that may enhance the virulence of cells or viruses containing the undefined mutations.Type: GrantFiled: March 21, 2022Date of Patent: December 13, 2022Assignee: New England Biolabs, Inc.Inventors: Nathan Tanner, Yinhua Zhang, Eric Hunt, Gregory Patton, Guoping Ren, Zhiru Li, Andrew Barry, Nicole Nichols, Catherine B. Poole, Harriet M. Strimpel, Ivan R. Correa, Jr., Clotilde Carlow, Esta Slayton
-
Publication number: 20220213564Abstract: Kits and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The kits and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The kits and methods utilize in various combinations, reversible inhibitors of kit components, thermolabile enzymes, poloxamers, various salts, indicators and one or more Loop-Mediated Isothermal Amplification (LAMP) primer sets for detecting single and/or multiple targets and variants of the targets including SARS-CoV-2 targets and variants thereof in a single reaction. The kits and methods permit detection of the target nucleic with similar sensitivity regardless of the presence of undefined mutations that may enhance the virulence of cells or viruses containing the undefined mutations.Type: ApplicationFiled: March 21, 2022Publication date: July 7, 2022Applicant: New England Biolabs, Inc.Inventors: Nathan Tanner, Yinhua Zhang, Eric Hunt, Gregory Patton, Guoping Ren, Zhiru Li, Andrew Barry, Nicole Nichols, Catherine B. Poole, Harriet M. Strimpel, Ivan R. Correa, JR., Clotilde Carlow, Esta Slayton
-
Patent number: 11345970Abstract: Kits and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The kits and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The kits and methods utilize in various combinations, reversible inhibitors of kit components, thermolabile enzymes, poloxamers, various salts, indicators and one or more Loop-Mediated Isothermal Amplification (LAMP) primer sets for detecting single and/or multiple targets and variants of the targets including SARS-CoV-2 targets and variants thereof in a single reaction. The kits and methods permit detection of the target nucleic with similar sensitivity regardless of the presence of undefined mutations that may enhance the virulence of cells or viruses containing the undefined mutations.Type: GrantFiled: August 19, 2021Date of Patent: May 31, 2022Assignee: New England Biolabs, Inc.Inventors: Nathan Tanner, Yinhua Zhang, Eric Hunt, Gregory Patton, Guoping Ren, Zhiru Li, Andrew Barry, Nicole Nichols, Catherine B. Poole, Harriet M. Strimpel, Ivan R. Correa, Jr., Clotilde Carlow, Esta Slayton
-
Publication number: 20210404024Abstract: Kits and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The kits and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The kits and methods utilize in various combinations, reversible inhibitors of kit components, thermolabile enzymes, poloxamers, various salts, indicators and one or more Loop-Mediated Isothermal Amplification (LAMP) primer sets for detecting single and/or multiple targets and variants of the targets including SARS-CoV-2 targets and variants thereof in a single reaction. The kits and methods permit detection of the target nucleic with similar sensitivity regardless of the presence of undefined mutations that may enhance the virulence of cells or viruses containing the undefined mutations.Type: ApplicationFiled: August 19, 2021Publication date: December 30, 2021Applicant: New England Biolabs, Inc.Inventors: Nathan Tanner, Yinhua Zhang, Eric Hunt, Gregory Patton, Guoping Ren, Zhiru Li, Andrew Barry, Nicole Nichols, Catherine B. Poole, Harriet M. Strimpel, D.Phil., Ivan R. Correa, Jr., Clotilde Carlow, Esta Slayton
-
Publication number: 20200399318Abstract: Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.Type: ApplicationFiled: September 9, 2020Publication date: December 24, 2020Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The University of Tokyo, New England Biolabs, Inc.Inventors: James Inglese, Patricia Dranchak, Ryan MacArthur, Hiroaki Suga, Hao Yu, Clotilde Carlow, Zhiru Li
-
Patent number: 10808010Abstract: Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.Type: GrantFiled: August 10, 2017Date of Patent: October 20, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The University of Tokyo, New England Biolabs, Inc.Inventors: James Inglese, Patricia Dranchak, Ryan MacArthur, Hiroaki Suga, Hao Yu, Clotilde Carlow, Zhiru Li
-
Publication number: 20190169234Abstract: Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.Type: ApplicationFiled: August 10, 2017Publication date: June 6, 2019Applicants: The United States of America, as represented by the Secretary, Dept, of Health and Human Services, The University of Tokyo, New England Biolabs, Inc.Inventors: James Inglese, Patricia Dranchak, Ryan MacArthur, Hiroaki Suga, Hao Yu, Clotilde Carlow, Zhiru Li
-
Publication number: 20060111848Abstract: Present embodiments of the invention describe computational methods for performing a systematic, genome-wide search for novel drug targets in pathogenic organisms for example, the human filarial parasites. Cofactor independent phosphoglycerate mutase (iPGM) was identified by this search as a candidate target for identifying therapeutic agents for use in treating animal or plant subjects infected with parasitic nematodes, microbial pathogens including microsporidia, fungi etc. A consensus amino acid or nucleotide sequence that characterizes iPGM is further provided.Type: ApplicationFiled: December 22, 2005Publication date: May 25, 2006Applicant: New England Biolabs, Inc.Inventors: Clotilde Carlow, Yinhua Zhang, Jeremy Foster, Sanjay Kumar